$HSCS News

HeartSciences Announces Commercial Release Of MyoVista Insights Version 1.3, Platform Update Introducing MyoVista Insights AI-ECG Algorithm Marketplace

HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™

HeartSciences Signs Commercial Agreement With St. Vincent Health, Critical Access Hospital Serving Lake County, Colorado, To Deploy MyoVista Insights Platform

HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting

HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings

Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $8

HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Heart Test Laboratories Q3 EPS $(0.63) Beats $(0.86) Estimate

University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center

Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals

Ascendiant Capital Maintains Buy on HeartSciences, Raises Price Target to $9.2

HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

HSCS stock has given up its prior gain. HeartSciences shares were trading higher after the company reported better-than-expected Q2 EPS results.

HSCS stock has given up its prior gain. HeartSciences shares were trading higher after the company reported better-than-expected Q2 EPS results.

HeartSciences shares are trading higher after the company reported better-than-expected Q2 EPS results.

CORRECTION: Heart Test Laboratories Q2 EPS $(0.85) Beats $(1.69) Estimate, Sales $2.419K Miss $50.000K Estimate

Heart Test Laboratories Q2 EPS $(0.85) Beats $(1.69) Estimate, Sales $2.419M Beat $50.000K Estimate

HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device

HeartSciences Submits MyoVista wavECG Device To FDA For 510(k) Premarket Clearance